Shaw, L., Merz, N., Azziz, R., Stanczyk, F., Sopko, G., Braunstein, G., et al. (2008) Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: Results from the National Institutes of Health—National Heart, Lung, and Blood Institute sponsored women’s ischemia syndrome evaluation. Journal of Clinical Endocrinology & Metabolism, 93, 1276-1284.

has been cited by the following article:

• TITLE: PCOS and hyperandrogenism in type 1 diabetes

  AUTHORS: Susan Tibuni-Sanders, Shahla Nader

  KEYWORDS: Type 1 Diabetes Mellitus; Hyperandrogenism; PCOS; Metformin

  JOURNAL NAME: Open Journal of Obstetrics and Gynecology, Vol.2 No.1, March 31, 2012

  ABSTRACT: Women with both type 1 diabetes and polycystic ovarian syndrome (PCOS) represent a unique population, with long term implications on fertility and diabetic complications, which need to be addressed. The studies reviewed herein address the increased incidence of PCOS in women with type 1 diabetes. The leading theories suggest that the underlying pathophysiology is related to intensive insulin therapy and resulting ovarian hyperandrogenism. We have searched the literature to determine what studies have been done to address the role of insulin resistance and insulin sensitizers for reduction of hyperandrogenism in these patients. According to the available evidence, we conclude that metformin may have a role in reducing the androgenic picture in type 1 patients with PCOS and insulin resistance.